BFRG
Bullfrog AI Holdings, Inc. Common StockNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.72
P/S
97.27
EV/EBITDA
-1.41
DCF Value
$211,251.34
FCF Yield
-48659427.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
18.4%
Operating Margin
-5652.4%
Net Margin
-5569.6%
ROE
-273.2%
ROA
-231.4%
ROIC
-308.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-1.5M | $-0.13 |
| FY 2025 | $116.7K | $-6.5M | $-0.63 |
| Q3 2025 | $83.4K | $-1.6M | $-0.15 |
| Q2 2025 | $33.3K | $-1.4M | $-0.15 |
Trading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-2.29
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.